{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:54:53Z","timestamp":1784631293682,"version":"3.55.0"},"reference-count":76,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endoscopy"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n            Background Surveillance of nondysplastic Barrett\u2019s esophagus (NDBE) is recommended to identify progression to dysplasia; however, the most cost-effective strategy remains unclear. Mutation of TP53 or aberrant expression of p53 have been associated with the development of dysplasia in BE. We sought to determine if surveillance intervals for BE could be stratified based on p53 expression.<\/jats:p><jats:p>\n            Methods A Markov model was developed for NDBE. Patients with NDBE underwent p53 immunohistochemistry (IHC) and those with abnormal p53 expression underwent surveillance endoscopy at 1 year, while patients with normal p53 expression underwent surveillance in 3 years. Patients with dysplasia underwent endoscopic therapy and surveillance.<\/jats:p><jats:p>\n            Results On base-case analysis, the strategy of stratifying surveillance based on abnormal p53 IHC was cost-effective relative to conventional surveillance and a natural history model, with an incremental cost-effectiveness ratio (ICER) of $8258 for p53 IHC-based surveillance. Both the conventional and p53-stratified surveillance strategies dominated the natural history model. On probabilistic sensitivity analysis, the p53 IHC strategy ($28 652; 16.78 quality-adjusted life years [QALYs]) was more cost-effective than conventional surveillance ($25 679; 16.17 QALYs) with a net monetary benefit of $306 873 compared with conventional surveillance ($297 642), with an ICER &lt;$50 000 in 96% of iterations. The p53-stratification strategy was associated with a 14% reduction in the overall endoscopy burden and a 59% increase in dysplasia detection.<\/jats:p><jats:p>\n            Conclusion A surveillance strategy for BE based on abnormal p53 IHC is cost-effective relative to a conventional surveillance strategy and is likely to be associated with higher rates of dysplasia diagnosis.<\/jats:p>","DOI":"10.1055\/a-2317-8184","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T05:21:11Z","timestamp":1714713671000},"page":"727-736","source":"Crossref","is-referenced-by-count":7,"title":["Stratification of Barrett\u2019s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group"],"prefix":"10.1055","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-167X","authenticated-orcid":false,"given":"Shyam","family":"Menon","sequence":"additional","affiliation":[{"name":"Gastroenterology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom of Great Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[{"name":"Health Economist, School of Population Health, Curtin University, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad G.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Ragunath","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Perth, Australia"},{"name":"Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ajg.2015.322","article-title":"ACG Clinical Guideline: diagnosis and management of Barrett's esophagus","volume":"111","author":"NJ Shaheen","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"R Obermannova","year":"2022","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.3390\/cancers13184653","article-title":"Clinical and lifestyle-related prognostic indicators among esophageal adenocarcinoma patients receiving treatment at a comprehensive cancer center","volume":"13","author":"SG Dighe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.3390\/cancers15225410","article-title":"Molecular biology and clinical management of esophageal adenocarcinoma","volume":"15","author":"S Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14309\/ajg.0000000000001680","article-title":"Diagnosis and management of Barrett's esophagus: an updated ACG Guideline","volume":"117","author":"NJ Shaheen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2013-305372","article-title":"British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus","volume":"63","author":"RC Fitzgerald","year":"2014","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.gie.2019.05.012","article-title":"ASGE guideline on screening and surveillance of Barrett's esophagus","volume":"90","author":"B Qumseya","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jgh.12913","article-title":"Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma","volume":"30","author":"DC Whiteman","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1053\/j.gastro.2018.02.022","article-title":"The effect of endoscopic surveillance in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"154","author":"DC Codipilly","year":"2018","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cgh.2006.03.001","article-title":"Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus","volume":"4","author":"P Sharma","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2011.153","article-title":"Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study","volume":"106","author":"M Sikkema","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/gast.2001.25111","article-title":"Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma","volume":"120","author":"NS Buttar","year":"2001","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ajg.2015.322","article-title":"BOB CAT: a large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia","volume":"110","author":"C Bennett","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.gie.2014.01.009","article-title":"Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis","volume":"79","author":"S Singh","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ajg.2008.31","article-title":"Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review","volume":"104","author":"S Wani","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0034-1391966","article-title":"Clinical outcomes in patients with a diagnosis of \"indefinite for dysplasia\" in Barrett's esophagus: a multicenter cohort study","volume":"47","author":"P Sinh","year":"2015","journal-title":"Endoscopy"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1055\/s-0034-1391091","article-title":"Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study","volume":"47","author":"C Kestens","year":"2015","journal-title":"Endoscopy"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.gie.2019.07.037","article-title":"Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis","volume":"91","author":"R Krishnamoorthi","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa0808145","article-title":"Radiofrequency ablation in Barrett's esophagus with dysplasia","volume":"360","author":"NJ Shaheen","year":"2009","journal-title":"NEJM"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nrgastro.2011.38","article-title":"Esophagus: endoscopic therapy for flat, dysplastic Barrett esophagus","volume":"8","author":"AF Peery","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.gastro.2015.04.013","article-title":"Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett's esophagus and confirmed low-grade dysplasia","volume":"149","author":"AJ Small","year":"2015","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gie.2014.01.007","article-title":"Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus","volume":"80","author":"DI Fudman","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.gie.2020.03.3756","article-title":"Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus: long-term outcome of a randomized trial","volume":"92","author":"RE Pouw","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/gutjnl-2018-317513","article-title":"Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study","volume":"68","author":"SS Sami","year":"2019","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gutjnl-2014-308501","article-title":"Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry","volume":"64","author":"RJ Haidry","year":"2015","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/gutjnl-2015-309298","article-title":"Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II)","volume":"65","author":"KN Phoa","year":"2016","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1055\/s-0034-1392414","article-title":"Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry","volume":"47","author":"RJ Haidry","year":"2015","journal-title":"Endoscopy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/s0016-5085(89)80011-3","article-title":"Barrett's esophagus: development of dysplasia and adenocarcinoma","volume":"96","author":"W Hameeteman","year":"1989","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0029-1214612","article-title":"An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus","volume":"41","author":"A Das","year":"2009","journal-title":"Endoscopy"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1007\/s10620-018-5148-7","article-title":"Screening and surveillance for Barrett's esophagus: is it cost-effective?","volume":"63","author":"JM Inadomi","year":"2018","journal-title":"Dig Dis Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1055\/s-2004-825813","article-title":"Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients","volume":"36","author":"M Giovannini","year":"2004","journal-title":"Endoscopy"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1746.2010.06506.x","article-title":"Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations","volume":"26","author":"NG Hirst","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/gutjnl-2014-307197","article-title":"Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis","volume":"64","author":"F Kastelein","year":"2015","journal-title":"Gut"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cgh.2019.11.058","article-title":"Optimizing management of patients with Barrett's esophagus and low-grade or no dysplasia based on comparative modeling","volume":"18","author":"AH Omidvari","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.gie.2013.07.046","article-title":"Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus","volume":"79","author":"LG Gordon","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1371\/journal.pmed.0040067","article-title":"NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma","volume":"4","author":"PC Galipeau","year":"2007","journal-title":"PLoS Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.gastro.2018.03.047","article-title":"Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma","volume":"155","author":"MD Stachler","year":"2018","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jso.20359","article-title":"The molecular biology of esophageal adenocarcinoma","volume":"92","author":"LB Koppert","year":"2005","journal-title":"J Surg Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0960-7404(10)80021-0","article-title":"The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence","volume":"4","author":"W Polkowski","year":"1995","journal-title":"Surg Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1136\/gutjnl-2012-303594","article-title":"Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus","volume":"62","author":"F Kastelein","year":"2013","journal-title":"Gut"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/gcc.22220","article-title":"Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study","volume":"54","author":"AL Davelaar","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10620-019-05586-7","article-title":"Aberrant p53 immunostaining in Barrett's esophagus predicts neoplastic progression: systematic review and meta-analyses","volume":"64","author":"P Snyder","year":"2019","journal-title":"Dig Dis Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2021.10.038","article-title":"Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia","volume":"162","author":"M Redston","year":"2022","journal-title":"Gastroenterology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","article-title":"ACG Clinical Guideline: Diagnosis and management of Barrett\u2019s esophagus","volume":"111","author":"NJ Shaheen","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.cgh.2016.04.001","article-title":"Adverse events after radiofrequency ablation in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"14","author":"BJ Qumseya","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.gie.2012.03.252","article-title":"Adverse events of upper GI endoscopy","volume":"76","author":"ASGE","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"E1053","DOI":"10.1055\/a-1858-0945","article-title":"Comparative cost-effectiveness of three post-radiofrequency ablation surveillance intervals for Barrett's esophagus","volume":"10","author":"S Menon","year":"2022","journal-title":"Endosc Int Open"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1002\/cam4.2451","article-title":"Esophageal cancer treatment costs by phase of care and treatment modality, 2000\u20132013","volume":"8","author":"AC Tramontano","year":"2019","journal-title":"Cancer Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"JA McDougall","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1053\/j.gastro.2012.05.010","article-title":"The cost effectiveness of radiofrequency ablation for Barrett's esophagus","volume":"143","author":"C Hur","year":"2012","journal-title":"Gastroenterology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/03007995.2018.1552407","article-title":"A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom","volume":"35","author":"V Pollit","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1365-2036.2010.04450.x","article-title":"A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus","volume":"32","author":"PC Boger","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.gie.2007.07.019","article-title":"Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis","volume":"67","author":"A Rastogi","year":"2008","journal-title":"Gastrointest Endosc"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/ajg.2010.171","article-title":"Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated","volume":"105","author":"WL Curvers","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.gie.2015.12.036","article-title":"Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort","volume":"84","author":"R Krishnamoorthi","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"E430","DOI":"10.1055\/s-0043-106578","article-title":"Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis","volume":"5","author":"LL Fujii-Lau","year":"2017","journal-title":"Endosc Int Open"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.gastro.2018.04.011","article-title":"Development of evidence-based surveillance intervals after radiofrequency ablation of Barrett's esophagus","volume":"155","author":"CC Cotton","year":"2018","journal-title":"Gastroenterology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"SJ Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJM197703312961304","article-title":"Foundations of cost-effectiveness analysis for health and medical practices","volume":"31","author":"MC Weinstein","year":"1977","journal-title":"NEJM"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/0272989X9401400308","article-title":"Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment","volume":"14","author":"SB Cantor","year":"1994","journal-title":"Med Decis Making"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/j.1572-0241.1999.01276.x","article-title":"Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk","volume":"94","author":"D Provenzale","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1053\/j.gastro.2009.02.062","article-title":"A cost-utility analysis of ablative therapy for Barrett's esophagus","volume":"136","author":"JM Inadomi","year":"2009","journal-title":"Gastroenterology"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2036.2002.01146.x","article-title":"Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma","volume":"16","author":"A Sonnenberg","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10080","article-title":"Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling","volume":"10","author":"R Garside","year":"2006","journal-title":"Health Technol Assess"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/s0016-5085(03)00393-7","article-title":"Medical decision analysis of chemoprevention against esophageal adenocarcinoma","volume":"124","author":"A Sonnenberg","year":"2003","journal-title":"Gastroenterology"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/ajg.2011.255","article-title":"Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review","volume":"106","author":"NA Gray","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/gast.2002.31879","article-title":"Surveillance and survival in Barrett's adenocarcinomas: a population-based study","volume":"122","author":"DA Corley","year":"2002","journal-title":"Gastroenterology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/gutjnl-2017-314135","article-title":"Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia","volume":"67","author":"M di Pietro","year":"2018","journal-title":"Gut"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.gie.2007.12.015","article-title":"Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry","volume":"68","author":"RA Ganz","year":"2008","journal-title":"Gastrointest Endosc"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/1055-9965.EPI-15-1164","article-title":"A tissue systems pathology assay for high-risk Barrett's esophagus","volume":"25","author":"RJ Critchley-Thorne","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mpdhp.2015.04.001","article-title":"p53 Immunohistochemistry as a biomarker of dysplasia and neoplastic progression in Barrett's oesophagus","volume":"21","author":"PV Kaye","year":"2015","journal-title":"Diagn Histopathol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/dote.12372","article-title":"Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma","volume":"29","author":"SM Brankley","year":"2016","journal-title":"Dis Esophagus"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/01.pas.0000213268.30468.b4","article-title":"AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease","volume":"30","author":"R Dorer","year":"2006","journal-title":"The American journal of surgical pathology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/labinvest.3700481","article-title":"Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus","volume":"86","author":"E Sabo","year":"2006","journal-title":"Lab Invest"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/CEOR.S221741","article-title":"A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett's esophagus","volume":"11","author":"J Hao","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1016\/j.cgh.2022.02.033","article-title":"Prediction of progression in Barrett's esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies","volume":"20","author":"PG Iyer","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2317-8184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:30:51Z","timestamp":1730806251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2317-8184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":76,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,27]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2317-8184","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0013-726X","1438-8812"],"issn-type":[{"value":"0013-726X","type":"print"},{"value":"1438-8812","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,2]]},"published":{"date-parts":[[2024,5,2]]}}}